Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Down 7.21%
As of Thursday, August 13, Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 7.21%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
Commentary & Analysis
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Up 5.45%
As of Monday, July 27, Atara Biotherapeutics, Inc.’s ATRA share price has surged by 5.45%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Down 7.00%
As of Friday, July 17, Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 7.00%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Up 6.09%
As of Wednesday, July 15, Atara Biotherapeutics, Inc.’s ATRA share price has surged by 6.09%, which has investors questioning if this is right time to sell.Michael Rose
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Down 5.42%
As of Tuesday, July 14, Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 5.42%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $94.2 | $286.3 | 21% |
|
| Shares Out (Mil) | 15.0 | 54.2 | 26% |
|
| Institutional Ownership | 89.5% | 92.8% | 57% |
|
| Float (Mil) | 3.7 | 39.7 | 10% |
|
| Beta | 0.10 | 0.94 | 9% |
|
| Avg Daily Volume (000s) | 58 | 534 | 29% |
|
| Price Change (52-week) |
(18.3%) | 58.7% | 30% |
|
| Growth | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | 16.1% | (10.1%) | 66% |
|
| EPS (5yr) | 15.2% | 16.0% | 57 |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | (15.2%) | (15.6%) | 50% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 1 | 1 | 3 | |
| Current EPS | ($0.330) | ($1.270) | $1.110 | |
| Month Ago EPS | ($0.205) | ($0.880) | $1.270 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.300) | ($1.230) | $1.637 | |
| Year/Year Chg | 2.5% | (149.4%) | (71.3%) | |
| Financials | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $6 | $37 | 7% |
|
| Net Income (TTM) (Mil) | ($17) | ($43) | 25% |
|
| EPS (TTM) | ($1.185) | ($1.400) | 19% |
|
| Operating Cash Flow (TTM) (Mil) | ($22) | ($31) | 14% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $9 | $4 | 27% |
|
| Enterprise Value (Q1) (Mil) | $88 | $160 | 20% |
|
| Valuation | ATRA | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.77 | na |
|
| P/E | na | 19.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.0 | na |
|
| Ratios | ATRA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 75.3% | 64.2% | 85% |
|
| Net Margin | (269.4%) | (75.9%) | 3% |
|
| ROA | (57.6%) | (47.3%) | 10% |
|
| ROE | 46.3% | (55.0%) | 92% |
|
| Liabilities to Assets | 276.0% | 29.6% | 99% |
|
| F-Score | 2 | 2 | 7% |
|
Atara Biotherapeutics, Inc. did not pass any screens on 8/20/2026.
